49
Participants
Start Date
March 31, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
April 30, 2014
Alefacept
Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
Placebo
Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
The Children's Hospital of Philadelphia, Philadelphia
University of Maryland, Baltimore
University of North Carolina, Durham
Emory University, Atlanta
Indiana University, Indianapolis
University of Iowa Hospital & Clinics, Iowa City
Children's Mercy Hospitals and Clinics, Kansas City
Creighton University, Omaha
University of Texas Southwestern Medical Center, Dallas
Barbara Davis Center for Childhood Diabetes - University of Colorado, Aurora
University of Arizona, Tucson
Children's Hospital of Los Angeles, Los Angeles
University of California - San Francisco, San Francisco
Benaroya Research Institute at Virginia Mason, Seattle
Massachusetts General Hospital, Boston
Collaborators (1)
Immune Tolerance Network (ITN)
NETWORK
Juvenile Diabetes Research Foundation
OTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH